Has been in use for the past 55 years in about one-fourth of the world's countries

PlaqX Forte

PlaqX Forte therapeutic formulation has been time-tested and used in over 501 countries for the past 55 years. Originally developed to dissolve fatty embolous in pre- and post-trauma surgery, as well as treating liver disease2 , its use shifted to treating plaque deposits in the 1990’s whose therapy include removal of fatty and hardened plaque from blood vessels.

PlaqX Forte for Anti-Aging

Eventually, PlaqX Forte’s formulated therapy became a treatment in its own right due to consistent and effective therapeutic results. The formula used in PlaqX Forte not only clears fatty and hardened plaque, it also causes significant effect on a person’s overall appearance by way of restoring cellular health including skin cells. Patients undergoing plaque therapy were recorded to start looking younger and healthier after they have had about 20 treatments.


Disclaimer: Contents in this site are for informational purposes only. Always seek the advice of a medical doctor or a qualified health provider should you have questions regarding a medical condition or a medical treatment.


1 Elevation of HDL, LDL, and liver enzymes in the beginning which normalize with continuing treatment

Leuschner, F. A. Leuschner. Research report no. 0050/84 of December 27, 1983
Maeda, A. et al. Gendai no Shinryo 22 (1980) 189-192 and 1461-1465
Fasoli, A.  Therap. Select. Risk/Benefit Assess. Hypolipid. Drugs
G. Ricci et al. (eds.) Raven Press: New York 1982, 257-262
Suo, T. et al.   Kiso to Rinsho 15 (1981) 3046-3051
Belousova, S.S. et al.  Kardiologiya 25 (1985) 112-115
Izumi, H.  et al. 11th Proceed Jap. Atheroscl. Socl, Tokyo 1979
Nakamura, H.  et al. Jap J. New. Rem. Clin. 22 (1973) 1565-1575
Spigai, C. Med. Heute 19 (1970) 197-198
Thurnherr A. Therapiewoche 7 (1956) 116
Friehe, H., R. Fontaine Report no. 840160 of December 16, 1978
Arsenio, L.  et al. Clin. Ter. 114 (1985) 117-127
Tomasevic, M. Unpublished report no. 842746
Takahashi, S.  Shinryo to Shinyaku 17 (1980) 3051-3064
 Blagosklonov, A.S.  et al. Kardiologiya 26 (1986) 35-38
Angina Pectoris  
Serkova, V.K. Klin. Med. (Moscow) 64 (1986) 91-95
Spesivtseva, V. G. et al., Lipostabil Symposium Moscow, Nov. 1984
Kalmykova, V.I., E. B. Zakharova, Sov. Med. 4 (1989) 5-9
Peripheral Vascular Klemm, J. In: Phosphatidylcholine. H. Peeters (ed.) Springer: Berlin 1976, 237-243
Luczac, Z., R. Leutschaft.  Unpublished report no. 842762
Pristautz, H.  Munch. Med. Wschr. 117 (1975) 583-586
Hevelke, G. et al.  Med. Welt 30 (1980) 593-602  
Liver disease  Salvioli, G. et al. Il Fegato 21 (1975) 5-25 and: 4th Int. Sympos. Atheroscl., Tokyo 1976 and:
Diab. Obes. Hyperlipoprot., Cupaldi, V. et al. (eds.), Academic Press: New York 1987  Salvioli, G.  Scand J. Gastroenterology 12 (1977) 841-847
Salvioli, G. et al. Gut 19 (1978) 844-850
Gaskina, T.K. et al. Voprosy meditsinskoi khimii 331 (1987) 96-99  
Cell Membranes  
Ehrly, A.M. Report no. 842276 of March 17, 1975 – and R. Blendin in: Phosphatidylcholine, H. Peeters (ed.) Springer: Berlin 1976, 228-236
Blagosklonov, A.S. et al. Kardiologiya 26 (1986) 35-38 3 Nei’mark Al, Zhukov, VN et al. Use of isradipine and EPL for protection of the kidney during extracorporal lithotripsy Urologiia I Nefrologiia. (6):19-21, 1998 Nov-Dec
4 Kuntz, E. The “essential” phospholipids in hepatology – 50 years of experimental and clinical experiences Z Gastroenterol (Suppl 2) 1991: 29:7-13